Actelion
Actelion ready to launch Uptravi after FDA approval
December 22, 2015Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag
Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …
Actelion confirms takeover talks with ZS Pharma
September 11, 2015Research and Development, Sales and Marketing Actelion, Shire, ZS Pharma, mergers and acquisitions
Swiss drugmaker Actelion has entered discussions with US biotech company ZS Pharma, over a takeover thought to be worth $2.5 …
Shire makes £12 billion move for Actelion
June 8, 2015Sales and Marketing Actelion, Shire, brett wells, nps pharma
Not a week goes by without a big pharma merger story, and now it’s the turn of Dublin-headquartered Shire that …
Actelion becomes latest recruit to join PatientsLikeMe
August 6, 2014Medical Communications, Research and Development, Sales and Marketing Actelion, PatientsLikeMe, digital
PatientsLikeMe and Actelion have come together in order to help create a new patient-reported outcomes tool for the rare form …
Positive CHMP verdicts for Actelion and Lundbeck
October 28, 2013Sales and Marketing Actelion, CHMP, FDA, Lundbeck
Actelion and Lundbeck both took a step closer to EU approval for two drugs seen as pivotal to their future …
Actelion to buy Ceptaris
August 1, 2013Sales and Marketing Actelion, FDA, ceptaris, valchlor
The US arm of Swiss speciality pharma group Actelion is in line to pay $250 million to buy private firm …
Jobs under threat in Actelion cost saving
July 12, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Actelion, R&D, Tracleer, cuts
Swiss speciality pharmaceutical company Actelion has unveiled a new cost saving plan which could include the loss of 260 jobs …
Actelion boosted by trial success
April 30, 2012Research and Development, Sales and Marketing Actelion, Tracleer, almorexant, macitentan
Actelion’s pulmonary arterial hypertension drug macitentan has met its primary endpoint in a Phase III trial. The news comes after …
Crisis in the boardroom: 2011’s most dramatic departures
January 11, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, KV pharmaceuticals, Kindler, Pfizer, management
In December 2010, Jeffrey Kindler, the chief executive of Pfizer suddenly announced his departure from the company.His abrupt exit made …
Actelion’s MS candidate shows promise
August 2, 2011Research and Development Actelion, MS
Actelion’s prospective multiple sclerosis pill ponesimod has cheered the company by meeting its primary endpoint in a phase IIb trial. …
Actelion plans biotech start-up
June 20, 2011Research and Development Actelion, biotech
Swiss biopharmaceutical company Actelion is planning to launch a biotech start-up that would run separately from the main company. It …
Elliott maintains pressure on Actelion
April 15, 2011Sales and Marketing Actelion, pharma mergers and acquisitions
Investment firm Elliott Advisors is maintaining its push for a new leadership team at Actelion.The investment firm is the biggest …
Actelion defends itself against investor aggression
March 9, 2011Sales and Marketing Actelion, Tracleer, almorexant
Swiss biotech firm Actelion is mounting a defence of its management board and strategy following an offensive by a shareholder …
GSK and Actelion drop insomnia treatment
January 30, 2011Research and Development Actelion, GSK, insomnia
Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.Almorexant a dual …
Tracleer continues to fuel Actelion growth
February 19, 2010Sales and Marketing Actelion, Tracleer
Actelion has posted a 20% increase in revenue on the strength of its pulmonary hypertension treatment Tracleer. The drug saw …
Latest content
